[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606862":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":38,"collaborators":10,"id":41,"slug":10,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":52,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Federico II University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Standard group",null,"IGC group",[13],{"name":14,"affiliation":5,"role":15},"Giovanni Aprea, Prof.","STUDY_DIRECTOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Dr. Giuseppe Palomba, MD, Phd fellow","CONTACT","+393381155483","giuseppe.palomba@unina.it",[23],{"facility":24,"status":25,"city":26,"state":10,"zip":10,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Università degli Studi di Napoli, Federico II","RECRUITING","Naples","Italy","IT",{"type":30,"coordinates":31},"Point",[32,33],14.26811,40.85216,{"lat":33,"lon":32},[36],{"name":37,"role":19,"phone":20,"phoneExt":10,"email":21},"Giuseppe Palomba",{"type":39,"investigatorFullName":37,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100606862",false,"NCT07181070","The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor","The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor: a Prospective Study","Inclusion Criteria:\n\n* patients with achalasia of type I and II\n* patients undergoing laparoscopic Heller-Dor\n* patients older than 18 years\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age;\n* Uncooperative patients and\u002For patients unable to provide informed consent\n* ASA ≥4\n* BMI ≥30\n* Patients previously treated with other endoscopic\u002Fsurgical procedures (botulinum toxin injections, dilation, POEM, myotomy)\n* Patients with achalasia type III\n* Patients with megaesophagus\n* Allergy to dyes or contrast agents included in the protocol (e.g., indocyanine green, barium, gastrografin)","ALL","18 Years",{"count":50,"type":51},70,"ESTIMATED","1 Year","OBSERVATIONAL","The aim this prospective observational study is to evaluate the role of Indocyanine Green Fluorescence (ICG) in patients with achalasia underwent to Heller-Dor laparoscopic. The main gol are:\n\n* If with use of ICG iatrogenic mucosal leaks can be identified and, if necessary, improve the myotomy.\n* Assess the need for postoperative radiographic control using esophagogastric radiography with gastrografin.\n* Compare clinical characteristics, perioperative outcomes, and 12-month postoperative follow-up between the two populations.",[56,57,58,59],"Achalasia, Esophageal","Achalasia","Indocyanine Green (ICG)","Indocyanine Green",[61,62,63],"achalasia","Laparoscopic Heller-Dor","Indocyanine Green Fluorescence","2025-09-18",{"date":66,"type":67},"2025-09-23","ACTUAL",{"date":69,"type":67},"2022-11-01",{"date":71,"type":51},"2026-10-31",{"name":5,"class":6},1]